On March 23, 2026, Swiss pharma giant Novartis announced plans to invest over 3.3 billion Chinese yuan (approximately $480 million) to bolster its industrial and research infrastructure in China. This move aligns Novartis with a growing wave of multinational pharmaceutical companies expanding their footprint in the country.
Key investment breakdowns:
-
Beijing Plant Upgrade (1.5 billion yuan): Funds will be channeled toward constructing new factory buildings and installing advanced equipment for aseptic preparation, liquid filling, and packaging. Established in 1987, the Beijing site is a vital global node with a current capacity of 3 billion tablets and capsules annually.
-
Shanghai R&D Expansion (1.8 billion yuan): Novartis is initiating the second phase of its Shanghai research campus. The plan involves accelerating Phase 1 and 2 clinical trials while actively seeking strategic collaborations with local Chinese biotech firms to strengthen its pipeline.
-
Pioneering Radiopharmaceuticals: The company is finalizing its first Chinese radioligand therapy (RLT) manufacturing site in Zhejiang province to supply advanced oncology treatments (such as Pluvicto and Lutathera). Novartis is also calling for regulatory improvements to streamline hospital access for nuclear medicines.
This renewed commitment follows similar large-scale investments from peers, including AstraZeneca’s $15 billion China pledge and Eli Lilly’s $3 billion manufacturing upgrade, highlighting China’s central role in the global pharmaceutical industry’s long-term strategy.